Courtney S P, Williams S, Mansel R E
Department of Surgery, University of Wales College of Medicine, Cardiff, United Kingdom.
J Cancer Res Clin Oncol. 1993;119(3):127-30. doi: 10.1007/BF01229525.
Monoclonal antibodies (mAb) raised to Ca1 and 323/A3 proteins have been suggested as markers of the premalignant breast. To establish the validity of this hypothesis the immunohistochemical staining patterns of these mAb have been studied in two different groups of patients with benign breast disease. One group comprised patients with benign biopsies who later went on to develop breast cancer. The second group were patients with benign breast disease who have not developed breast cancer. The immunohistochemical staining patterns of the two groups were compared. The staining patterns between the groups, when ducto-lobular, apocrine metaplasia and fibroadenomatous tissue were analysed, was similar. This occurred both for Ca1 and 323/A3 mAb. We conclude that the antigens identified by these mAb will not enable prediction of cancer development.
针对Ca1和323/A3蛋白产生的单克隆抗体(mAb)被认为是乳腺癌前病变的标志物。为了验证这一假设,对两组不同的良性乳腺疾病患者的这些mAb的免疫组织化学染色模式进行了研究。一组包括活检为良性但后来患乳腺癌的患者。第二组是未患乳腺癌的良性乳腺疾病患者。比较了两组的免疫组织化学染色模式。分析导管小叶、大汗腺化生和纤维腺瘤组织时,两组之间的染色模式相似。Ca1和323/A3 mAb均是如此。我们得出结论,这些mAb识别的抗原无法预测癌症的发展。